Flibanserin Online Prescription:
Cost, Who Qualifies, and What to Check First

For ten years, flibanserin — brand name Addyi — was approved only for premenopausal women. On December 13, 2025, the FDA approved an expanded indication covering women under 65 with acquired, generalized HSDD, in the agency’s own words, independent of reproductive status. Postmenopausal women are now in the labeled population.

Most coverage says December 15. That’s the day Sprout Pharmaceuticals put out the press release. The FDA’s approval letter is electronically signed December 13, 2025 at 2:44 a.m. and states the approval is effective on the date of the letter. We link it below.

Starting the online evaluation is straightforward. The hard part — the part that decides whether you spend $317 and eight weeks on the wrong thing — is whether flibanserin is aimed at what’s actually going on. In midlife, there are several common explanations for low desire that this drug isn’t built for. We’ll show you all of them, with the real numbers, including the ones that aren’t on the homepage.

The HRT Indexis the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

The bottom line in one screen

Primary sources: FDA approval letter, NDA 022526/S-013, signed Dec 13, 2025 · FDA prescribing information, revised 12/2025 · addyi.com/getting-addyi · GoodRx · Drugs.com generic availability

Is this you? Or is it not?

Before you go further

The right online HRT provider isn’t the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference, your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can’t resolve those for you, use The HRT Index’s Find My HRT Path tool to match your situation to the right provider.

Find My HRT Path collects sensitive health information and is handled under our Consumer Health Data Privacy Policy.

Can you actually get a flibanserin online prescription?

Yes. A clinician licensed or otherwise legally permitted to treat you where you’re physically located can prescribe flibanserin through telehealth, subject to state law and their scope of practice. When Addyi launched in 2015, the FDA required prescribers and pharmacies to complete a certification program first. The FDA removed those certification and restricted-distribution requirements in October 2019 and determined in January 2025 that the REMS was no longer needed. The Medication Guide remains part of labeling.

Removing those requirements is what made ordinary telehealth prescribing and pharmacy dispensing practical for this drug. It’s not the only thing that matters — state law, the clinician’s scope, and an appropriate evaluation still govern whether you can be prescribed anything online.

But it cuts both ways. It means a menopause specialist can prescribe it. It also means a short questionnaire can.

The routes that actually exist

We reviewed the public pages, terms, and intake flows for each route below. We’ve separated what the provider states from what we independently checked.

Checked July 15, 2026. Sources: addyi.com/getting-addyi · Midi pricing & insurance · Midi low libido options · Sesame

Still unresolved on every route: refund terms for the online visit, what follow-up is included, and state-by-state availability of the dedicated route. Ask before you pay.

The manufacturer’s telehealth partner is BeyondMD. The pharmacy is PhilRx (NPI 1487163598, Columbus, Ohio). Those are the actual entities that will hold your medical history. You should know their names before you hand it over.

What a good online visit looks like — and what it doesn’t

Whether it’s a questionnaire, a video call, or an office visit matters less than whether a real clinician reviews your history and you have a route back to them. A well-designed intake can collect all of this. A bad one can skip it in any format.

What does flibanserin cost online in 2026?

The manufacturer states a cash price of $149 a month through PhilRx, its partner pharmacy, with free shipping. Official pages also advertise conditional commercial-insurance offers — $20 a month on one page, $40 for a full year on another. The online visit is displayed at $19 in one place and $29 in another. When we checked on July 15, 2026, GoodRx showed an average-retail benchmark of $2,499.66 and a coupon price from $298.80.

Read that last number again.

The price ladder

This is the most expensive thing you can get wrong on this page, so here’s the whole ladder.

Checked July 15, 2026. addyi.com/getting-addyi · GoodRx. Prices vary by pharmacy, quantity, and location, and they change.

Same pill, same manufacturer. Against those two dated inputs, $2,499.66 versus $149 works out to roughly a 16.8× difference— decided by which channel you use. That’s illustrative arithmetic, not a promise about your pharmacy. But the shape of it is real.

What it actually costs to find out

The label says to discontinue after eight weeks if HSDD symptoms haven’t improved. So the real question isn’t “can I afford this forever.” It’s what does it cost to find out?

A scenario using prices displayed July 15, 2026. It doesn’t include follow-up, pharmacy, insurance, or other care costs that may not be publicly disclosed.

Roughly $320 and eight weeks.That’s the size of the bet. If it helps, you’ll know. If it doesn’t, the label tells you to stop.

Is there a generic flibanserin?

No.Drugs.com states plainly that the FDA has not approved a generic version of Addyi, and warns that fraudulent online pharmacies may try to sell an illegal one — potentially counterfeit, potentially unsafe. Patent analysts estimate the earliest possible generic entry around 2028, though that’s an estimate and can shift with litigation or licensing.

Anyone selling you “generic flibanserin” today is not a source you should trust. (Checked July 15, 2026 — Drugs.com. We re-check this monthly.)

Who does the FDA label cover now? The December 2025 change

On December 13, 2025, the FDA approved an expanded indication for Addyi covering women under 65 with acquired, generalized HSDD, independent of reproductive status. The current prescribing information reads: “ADDYI is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder.”Before this, the label covered premenopausal women only — which is why many health pages still say postmenopausal women can’t take it.

This made Addyi the first FDA-approved oral medication specifically indicated for acquired, generalized HSDD in qualifying postmenopausal women under 65. Vyleesi, the other approved HSDD drug, remains premenopausal-only.

Worth knowing how it happened: Sprout filed the supplement on March 17, 2025. The FDA acknowledged a major amendment in July 2025 that pushed the decision date back three months. The approval letter was signed by the Director of the FDA’s Division of Urology, Obstetrics, and Gynecology at 2:44 a.m. on December 13, 2025.

Where you fall

The stale-source audit

We checked what the internet was telling women about this in July 2026 — seven months after the label changed.

We’re not pointing this out to score points. We’re pointing it out because if you asked your own doctor about this in the spring and she said “that’s not for postmenopausal women,” she may have been reading something that was accurate in 2024 and isn’t now.It’s worth asking again.

What criteria does a clinician use to diagnose HSDD?

HSDD — hypoactive sexual desire disorder — isn’t the same thing as low libido. The FDA label defines it as low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. That last part makes it a diagnosis of exclusion, which is why the evaluation matters more than the prescription.

Flibanserin treats a specific condition. Not “low libido.” The label sets four criteria. A clinician has to work through all of them — and you can walk in prepared.

1. Acquired

You had desire. Then it changed.

If desire was never really there — not in your twenties, not ever — that pattern is described as lifelong rather than acquired. It’s a different thing, and flibanserin wasn’t studied for it.

2. Generalized

The label’s word is generalized: it occurs regardless of the type of stimulation, situation, or partner.

If the pattern shifts substantially — it comes back on vacation, or with someone new — that may be situational rather than generalized. Only a clinician can sort that out, but it’s worth noticing before your visit.

3. Marked distress or interpersonal difficulty

The label allows either one.

And here’s the part worth saying plainly: low desire is not automatically a disorder.If your desire changed and you’ve made peace with it, that isn’t a medical problem. Nobody gets to pathologize it — not a partner, not a telehealth funnel, and not us.

But if it’s causing you real distress, or real difficulty between you and someone you love, that’s what the criterion describes. Bring it up. It’s not a small thing and it isn’t vanity.

4. Nothing else explains it

This is the one the evaluation has to earn. The label says HSDD is not the diagnosis when the low desire is due to a co-existing medical or psychiatric condition, relationship problems, or a medication or other drug. Look at what else is common in midlife:

Yale OB/GYN Mary Jane Minkin, speaking to Healthline about the expanded approval, described her first question for a patient who raises libido issues: “How’s your vagina feeling? Are you comfortable?” (Healthline, Dec 19, 2025)

That’s the discipline in one question. Ask about comfort before you ask about desire.

What to bring to your consult

Print this. Take it. It’s the difference between a fifteen-minute visit that guesses and one that decides.

• Every medication you take — prescription, over-the-counter, supplements, herbals. All of it
• Any liver history, including fatty liver
• How much you drink in a normal week. Be accurate. This one has a boxed warning attached
• Any fainting, near-fainting, or low blood pressure
• Whether sex is painful, and whether dryness, bleeding, or urinary symptoms are present
• When your desire changed, and what else changed around that time
• Whether it’s everywhere or only in certain situations
• What you want. “I want to want it again” is a real, legitimate treatment goal. Say it out loud

How does flibanserin work, and how long does it take?

Flibanserin is a non-hormonal, centrally acting medication taken once nightly at bedtime — not before sex. The FDA label states that its mechanism of action in treating HSDD is not known. Some women notice a change within a few weeks, but the label’s decision point is eight weeks: discontinue if HSDD symptoms haven’t improved.

What the label does say: flibanserin has high affinity for certain serotonin receptors, acting as an agonist at 5-HT1A and an antagonist at 5-HT2A, with moderate activity at some others. How that translates into desire is not established. Anyone telling you it “rebalances your brain chemistry” is going past what the FDA label supports.

It reaches steady state in about three days and has a half-life of roughly 11 hours. It’s dosed at bedtime because taking it during waking hours raises the risk of low blood pressure, fainting, injury, and sedation.

What did the FDA trial actually show for postmenopausal women?

In Study 6, the trial supporting the December 2025 expansion, postmenopausal women under 65 taking flibanserin reported an average of 0.9 additional satisfying sexual events per 28 days versus 0.6 on placebo — a placebo-adjusted difference of 0.4 events. Desire scores improved 0.3 points more than placebo on a 1.2-to-6 scale. The FDA reports these as statistically significant. They are group averages, and they are modest.

We’re reproducing the FDA’s own results in reader-facing form, because you deserve to see the actual size of what you’re deciding about.

Study 6 (NCT00996372), postmenopausal women under 65

Who was in it: 447 women randomized to flibanserin, 455 to placebo; the efficacy analysis included 430 and 451. Average age 55. Average relationship length: 21 years. Average time living with HSDD: about 5 years.
Source: FDA prescribing information, section 14.2, revised 12/2025

As rough group-average arithmetic, 0.4 events per 28 days is about one additional satisfying experience every ten weeks. That’s an average across a trial population — not a prediction for you.

Six things the label doesn’t advertise

We reviewed the current 28-page prescribing information. For postmenopausal women specifically — the newly covered group — the evidence has real gaps:

1. No dedicated alcohol study was done in postmenopausal women. The label says it directly: dedicated alcohol-interaction studies were not conducted in postmenopausal women. Every alcohol study behind that boxed warning was done in premenopausal women or men. (§6.1)
2. No driving study either. The label states the effect on driving performance in postmenopausal women was not evaluated. (§14.3)
3. Very little long-term data. Of 801 postmenopausal women who received flibanserin in trials, 460 were exposed for at least six months — and only 23 were exposed for more than six months. (§6.1)
4. One of the two postmenopausal trials was discontinued prematurely. Efficacy for this population was established in Study 6; Study 7 was stopped early. (§6.1, §14.2)
5. The trial population was healthier than average. Study 6 excluded women with uncontrolled high blood pressure, uncontrolled diabetes, cardiovascular disease, uncorrected thyroid disorders, and psychiatric disorders. That limits how well the results generalize to medically complex patients. (§6.1)
6. Serious adverse reactions were reported more often on the drug — 1.5% versus 0.7% on placebo in the postmenopausal trials. (§6.1)

None of that means don’t take it. It means part of the honest answer to “is this safe for me?” is “here is exactly what hasn’t been studied yet”— and you should hear that from someone before you hear it from nobody.

What the label reports on side effects

The label reports adverse reactions separately for the premenopausal and postmenopausal trial programs. These were different trials, and the FDA states directly that rates observed in one clinical trial program cannot be directly compared with another and may not reflect what happens in practice. Read each column against its own placebo — not across the table.

One label detail worth raising if it applies to you: in the premenopausal trials, 43% of participants reported using hormonal contraceptives, and flibanserin-treated women who did reported more dizziness, somnolence, and fatigue. Oral contraceptives are weak CYP3A4 inhibitors and raise flibanserin exposure about 1.4-fold. If you’re perimenopausal and still on a contraceptive pill, that’s a conversation to have.

What contraindications and interactions can rule out Addyi?

Flibanserin carries a boxed warning for severe low blood pressure and fainting. It is contraindicated with moderate or strong CYP3A4 inhibitors, in patients with any degree of hepatic impairment, and in anyone with known hypersensitivity. The alcohol rule is specific: wait at least two hours after one or two standard drinks before your bedtime dose, and skip the dose entirely after three or more.

CYP3A4 is a liver enzyme that clears flibanserin. Block it, and the drug builds up. That’s the mechanism behind the warning.

And the contraindicated list reads uncomfortably like a midlife medicine cabinet.

Hard contraindications

Source: FDA prescribing information §4, §5.2, §7. Not every antifungal or antibiotic is contraindicated — these specific ones are. Check every new medicine with your prescriber or pharmacist.

Why fluconazole is the one to circle

The FDA required an interaction study of flibanserin with fluconazole. They stopped the study early. Three of 15 healthy subjects (20%) developed low blood pressure or fainting requiring intervention. One became unresponsive with a blood pressure of 64/41 mm Hg and needed to be taken to a hospital emergency department for IV saline. Concomitant use raised flibanserin exposure 7-fold.

Fluconazole is a single pill from urgent care or a telehealth visit — the kind of thing you don’t file mentally under “a medication” because you took one and it was over.

Not contraindications, but they matter

These add to flibanserin’s sedative effect rather than blocking its clearance. Different mechanism, real consequences:

• Diphenhydramine — Benadryl, ZzzQuil, Tylenol PM, Advil PM
• Opioids, benzodiazepines, prescription sleep aids

Menopausal women with insomnia take these constantly, and nobody files Tylenol PM under “drug interaction.” The label lists CNS depressants as a clinically significant interaction to discuss with your prescriber.

Also flagged in the label: St. John’s Wort (reduces flibanserin exposure — not recommended), ginkgo, resveratrol, and cimetidine (multiple weak CYP3A4 inhibitors can add up), fluoxetine and oral contraceptives (weak CYP3A4 inhibitors), and strong CYP2C19 inhibitors including proton pump inhibitors and SSRIs.

The alcohol rule, exactly as written

One standard drink = one 12 oz beer (5%), 5 oz wine (12%), or 1.5 oz of spirits.

This isn’t “no alcohol ever” — that was the 2015 label, and half the internet still repeats it. It’s a timing rule. But it’s a timing rule you follow every night, indefinitely.

Also in the label

• Don’t drive or do anything requiring full alertness for at least 6 hours after your dose, and until you know how it affects you
• Bedtime only. Never during the day
• Miss a dose? Skip it. Take the next one at bedtime the next day. Don’t double up
• Digoxin: flibanserin increased digoxin exposure about 2-fold and peak concentration about 1.5-fold. Monitoring is recommended
• CYP2C19 poor metabolizers — roughly 2–5% of white and Black populations, 2–15% of Asian populations — clear it more slowly
• In a 2-year mouse study, malignant mammary tumors increased at 3× and 10× the clinical exposure. The label states the clinical significance is unknown. It’s in the label; you’d want to know

Flibanserin vs. testosterone vs. vaginal estrogen vs. Vyleesi

For a postmenopausal woman under 65 with distressing low desire, flibanserin is now the only FDA-approved oral option — but it isn’t the only evidence-based one. Transdermal testosterone, used off-label, is recommended for postmenopausal HSDD by a global consensus statement endorsed by more than ten medical societies. Vyleesi remains indicated for premenopausal women only.

Sources: FDA label 12/2025 · Global Consensus Position Statement, Davis SR et al., J Clin Endocrinol Metab 2019;104(10):4660–4666 · ISSWSH Clinical Practice Guideline, Parish SJ et al., J Sex Med 2021;18:849–867

What the testosterone guidance actually says

Precision matters here, because this is where a lot of sites get loose:

• The only evidence-based use of testosterone in women is HSDD in postmenopausal women. Not energy, not mood, not weight
• No FDA-approved female testosterone product exists in the U.S. Clinicians use male formulations at much lower female doses, off-label
• Testosterone is a Schedule III controlled substance. It requires a prescription from a licensed prescriber
• Monitoring is required. ISSWSH recommends baseline total testosterone and SHBG, rechecking 3–6 weeks after starting and within 6 weeks of a dose change, then every 4–6 months once stable
• A blood testosterone level cannot diagnose HSDD. If a clinic tests your level and uses that number to sell you testosterone, that is not what the guideline says to do
• Stop at about 6 months if it isn’t working
• Oral testosterone is not recommended — it worsens cholesterol
• Systemic DHEA is not recommended for HSDD in women with normal adrenal function
• ISSWSH does not recommend compounded testosterone for HSDD, citing inadequate efficacy and safety data and variability in concentration

That last point matters for how you read every “bioidentical” ad you’ve ever scrolled past. Compounded drugs are not FDA-approved — the FDA does not review them for safety, effectiveness, or manufacturing quality before marketing — and they are not equivalent to FDA-approved medication. On this specific question, the professional guideline says don’t.

What do real women say about flibanserin?

Patient reviews of flibanserin are unusually split. On Drugs.com, Addyi averages 4.1 out of 10 across 75 reviews, with 61% reporting a negative experience and 29% positive. On WebMD, it averages 3.8 out of 5 across 57 reviews, with a striking bimodal distribution.

These are self-selected, unverified patient reviews on two platforms with different scales, populations, prompts, and moderation. They can’t establish efficacy, safety, or how often a given result occurs. The trial data above is the evidence. This is the reputation snapshot.

What the numbers do tell you honestly: experiences on this drug vary a lot, and the middle is thin.Women tend to describe either something meaningful or nothing at all. That’s worth knowing before you start, because it sets a realistic expectation — and it’s why the eight-week decision point exists.

Three real reviews, chosen for honesty

None of these establish that flibanserin works, is safe, or that any result is typical. Reviews never can.

Will insurance cover flibanserin?

Coverage varies by plan. GoodRx notes Addyi isn’t covered by most Medicare and insurance plans. Sprout’s savings program excludes Medicare, Medicaid, TRICARE, VA, and other government healthcare programs — so those patients can’t use the manufacturer’s discount, though that’s separate from whether their plan covers the drug at all.

Sources: GoodRx · Sprout/PhilRx coupon terms. Checked July 15, 2026.

If your plan pushes back

Prior authorization may be required, depending on the plan. Have this ready:

1. The diagnosis in the chart — acquired, generalized HSDD, in those words
2. What you tried first, if the plan wants to see it
3. Chart notes addressing the exclusions — medical, psychiatric, relationship, medication
4. Ask the plan whether a formulary exception or appeal process is available, and what documentation it needs
5. PhilRx states it provides prior-authorization support on Addyi orders. Use it
6. Your fallback: $149 cash. Sometimes that beats a two-month appeal

Which route should you actually use?

If you already know the diagnosis and want the medication, the lowest published direct cash route among the options we checked on July 15, 2026 is Sprout’s own telehealth visit plus PhilRx at $149 a month. If you’re in midlife and the cause is still an open question, a clinician who can consider the full range of options is worth more than a faster prescription.

Where Midi earns its price is the part that decides this. Midi publicly lists flibanserin, bremelanotide, testosterone, hormone therapy, vaginal treatments, bupropion, and counseling among the options its clinicians may consider for low libido. Treatment is always up to the clinician, subject to state law, formulary access, and clinical judgment — no one can promise you a prescription.

A visit that could end in six different places asks different questions than a visit that can only end in one. The pill is the cheap part. The evaluation is what you’re actually buying.

Route by situation

What happens after you’re prescribed flibanserin

Once a prescription is issued, PhilRx confirms payment and ships to your door, or your prescription goes to a pharmacy you choose. You take one 100 mg tablet at bedtime — never during the day. The label notes most common adverse reactions began within the first 14 days. At eight weeks, you and your clinician decide, and the label says to discontinue if HSDD symptoms haven’t improved.

Weeks 1–2

Expect the possibility of dizziness, sleepiness, or nausea early. Track:

• Dizziness on standing — lie down immediately if it starts
• How you feel the next morning
• Whether “no driving for 6 hours” actually works with your life
• Whether the alcohol timing is realistic for you

Your eight-week check-in

Bring answers to these. Write them down as you go — memory is a poor witness eight weeks later.

• Has desire changed in a way you notice?
• Has the distress eased?
• Were side effects tolerable?
• Did you take it at bedtime, consistently?
• Any new medications since you started? Any at all
• Any fainting or near-fainting?

If the answer is no, the label says to discontinue. Stopping a medication that didn’t work isn’t a personal failure — it’s the point of having a decision date.

Don’t

• Double a missed dose. Skip it, take the next one at bedtime
• Take it in the morning. Ever
• Start any new prescription, over-the-counter medicine, or supplement without checking for an interaction. Certain antibiotics and antifungals matter most
• Keep going past eight weeks hoping it kicks in
• Treat the prescription as the end of the relationship

How we verified this page

We built this page under The HRT Index Verification Standard: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, full roster quarterly. Our recommendations are editorial conclusions based on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, access. (Our methodology)

What we actually verified

Medical and regulatory — primary sources

• The FDA approval letter for NDA 022526/S-013, electronically signed December 13, 2025
• The full 28-page prescribing information revised 12/2025 (Reference ID 5711186)
• Study 6 (NCT00996372) efficacy data, exclusion criteria, and adverse-reaction tables
• The label’s own statements that dedicated alcohol and driving studies were not conducted in postmenopausal women
• The fluconazole and ketoconazole interaction study results
• The Global Consensus Position Statement (2019) and ISSWSH Clinical Practice Guideline (2021)
• Vyleesi’s current premenopausal-only indication
• Drugs.com’s generic-availability record: no FDA-approved generic Addyi

Commercial — read on the source’s own pages, July 15, 2026

• addyi.com: $149/mo cash offer, $20/mo and $40/yr insured offers, $19 and $29 visit displays, PhilRx as pharmacy, BeyondMD as telehealth partner
• Sprout/PhilRx coupon terms, including government-program exclusions
• GoodRx: $2,499.66 average-retail benchmark, $298.80 coupon price, $2,869.69 dosage-table figure
• Midi: published flibanserin listing, $250/$150 self-pay pricing, PPO language, Medicaid and Medicare policies
• Sesame: general visit pricing floor, cash-pay-only model, controlled-substance policy, refund terms
• Drugs.com and WebMD review counts and distributions

What we did NOT verify

• Whether any provider will prescribe to you. Nobody can promise that
• Your insurance coverage. Plan-specific
• The final price at your pharmacy before an actual claim
• Which visit price you’ll see — official pages show $19 and $29
• The refund policy or included follow-up for the manufacturer-linked visit
• State-by-state availability of the dedicated route
• Any Addyi-specific listing on Sesame, in any state
• Whether Hers, Winona, or Inner Balance currently prescribe Addyi. We found no current evidence, so we don’t list them
• Firsthand use. We read published intake flows, terms, and pricing. We did not complete a visit

Our sources, in order of weight

1. FDA approval letters, prescribing information, and approval records
2. DailyMed
3. Professional guidelines (The Menopause Society, ISSWSH, Global Consensus Position Statement) and peer-reviewed literature
4. Provider pricing, formulary, and terms pages — read directly and dated
5. Public patient reviews — lived experience only, never evidence of efficacy or safety

Found something out of date? Prices and policies move faster than pages do. Tell us: corrections@thehrtindex.com · Corrections log

Frequently asked questions

One last thing

If you’re 52 and your desire changed and you’ve been quietly wondering whether this is just what happens now — it isn’t a character flaw, and you’re not imagining it. In one U.S. study cited by ISSWSH, 12% of women aged 45 to 64 reported decreased sexual desire with distress. And until December 2025, not one FDA-approved pill for it included you.

Now the label does. The average benefit in the trial was modest, and individual experiences vary a lot. But it exists, it costs about $320 and eight weeks to get your own answer instead of somebody else’s average, and qualifying postmenopausal women under 65 are finally in the labeled population.

The thing to get right isn’t whether to take it. It’s whether it’s aimed at the right target.